Orchid Of India, Pfizer Of U.S. Settle Patent Dispute Over Effexor XR
This article was originally published in PharmAsia News
Executive SummaryIndia's Orchid Chemicals and U.S. drug giant Pfizer agreed to an out-of-court settlement of a patent dispute over the extended-release version of Effexor XR (venlafaxine) antidepressant
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.